In some cancers, the activation of STAT6 is highly related to the increase of apoptosis inhibition, therefore, blocking the phosphorylation of this protein may be a mechanism triggered by Trimethylglycine to improve the response to 5-FU therapy. Here, STAT6 is linked to cancer.